Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.

Cancer medicine - 1 Nov 2015

Brown Austin L, Lupo Philip J, Okcu Mehmet Fatih, Lau Ching C, Rednam Surya, Scheurer Michael E

Abstract excerpt

Manganese superoxide dismutase (MnSOD), encoded by the SOD2 gene, is involved in the detoxification of superoxide anion. Superoxide is likely a source of oxidative stress in the cochlea following treatment with platinum agents and radiation. Therefore, we examined SOD2 variants in association with ototoxicity among cisplatin-treated childhood medulloblastoma patients. Blood samples were obtained from 71 eligible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cerebellar Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Cisplatin

Share to Genetic Association Studies

Share to Infant

Share to Medulloblastoma

Share to Superoxide Dismutase

Source

Open in PubMed Open full text

Identifiers

PMID: 26400460
DOI: 10.1002/cam4.516
PMCID: PMC4673994

Genes

SOD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.PMID 26400460Read ↗

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

Otoprotection in Children Treated for Cancer: A CODEPEH Review Using PRISMA Methodology on Pharmacological Agents, Biomarkers and Genetic SusceptibilitySemantic proximity Read ↗

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.Semantic proximity Read ↗

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.Semantic proximity Read ↗

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.Semantic proximity Read ↗

The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.Semantic proximity Read ↗

Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.Semantic proximity Read ↗

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.